Augurex is a biotechnology company that is focused on the development
of biomarkers, which are substances in the body that inform patient
conditions to assist in their diagnosis and to help optimize therapy
selection and patient management. Extracellular 14-3-3η protein
represents the company’s first biomarker and also serves as a
drug target for the potential treatment of rheumatoid arthritis (RA),
a particularly debilitative form of arthritis.
Recent Press Releases
05/29/2014 - Arthritis Blood Test: 14-3-3 eta Ground-Breaking Data
10/25/2013 - Rheumatoid Arthritis Blood Test (14-3-3eta) Data to be Presented at the World's Premier Arthritis Conference
11/14/2012 - Blood Marker Can Help Diagnose Rheumatoid Arthritis; New Data at the 2012 Annual Meeting of the American College of Rheumatology
10/09/2012 - Augurex Announces Exclusive License Agreement with Quest Diagnostics for the Development of Arthritis Biomarker 14-3-3η as a Testing Service in the U.S.
09/06/2012 - Exciting Update from the World of BC Biotechnology
06/14/2012 - Protein Measured by a Blood Test Marks Joint Erosions in Arthritis; Findings Reported at the Annual European Congress of Rheumatology
11/18/2011 - Novel Blood Test Identifies Patients with Early Rheumatoid Arthritis; Findings Reported at the American College of Rheumatology (ACR)
05/28/2011 - Augurex Reports Positive Data for RA Blood Test and Drug Target at the Annual European Congress of Rheumatology (EULAR)